Pian Biotechnology has initiated a Phase 1 clinical trial for PN-101, the world’s first mitochondrial therapy. The trial focuses on assessing safety, tolerability, and preliminary efficacy in patients with degenerative diseases linked to mitochondrial dysfunction.
The study will involve a small cohort of participants and will measure mitochondrial activity, cellular energy levels, and biological markers of degeneration. PN-101 aims to restore normal mitochondrial function, supporting energy production and cellular repair.
Mitochondrial dysfunction is associated with numerous conditions, including neurodegenerative diseases, metabolic disorders, and age-related degeneration. By targeting the source of cellular energy failure, PN-101 could provide therapeutic benefits that current treatments cannot offer.
The CEO of Pian Biotechnology stated, “Phase 1 marks a historic step toward pioneering mitochondrial therapies that can fundamentally change patient care.”
The trial will also generate data to guide future Phase 2 and 3 trials, optimize dosing, and expand potential applications. PN-101 is poised to be a first-in-class therapy, opening new avenues in regenerative medicine and offering hope for patients with chronic degenerative conditions.
